Command Palette

Search for a command to run...

AMBUJACEM

529.45-3.6 (-0.68%)

Quarterly ResultsProfit & LossBalance SheetCash Flow

Key Insights

POSITIVE
  • Net Sales increased significantly to ₹9888.61 crore in Q1 2025, showing strong demand recovery.
  • Operating profit improved to ₹1066.91 crore, indicating better cost management and efficiency.
  • Net profit surged to ₹1282.24 crore, reflecting enhanced profitability compared to earlier quarters.
NEGATIVE
  • Company experienced a cash flow shortfall with a 10% decrease this year [Dummy Data]
  • Company’s strategic partnerships have yet to generate expected growth. [Dummy Data]
  • Company’s EBITDA shrank at a CAGR of -8% over the past 3 years. [Dummy Data]
Quarterly Results Data
FieldTrendMar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25
Revenue
8,893.998,311.487,516.119,328.569,888.6110,289.109,174.4910,276.60
Expenses
7,741.317,566.917,023.498,347.688,821.709,256.698,375.599,941.46
Operating Profit
1,152.68744.57492.62980.881,066.911,032.41798.90335.14
Other Income
233.46354.72374.031,352.24573.26256.09257.0487.32
Interest
92.9167.8166.8566.9914.2967.1476.8258.85
Depreciation
453.06467.43551.96663.98786.35861.57885.15959.03
Profit Before Tax
1,601.141,102.68712.672,336.071,779.561,332.63837.53412.41
Tax
75.36313.05239.78-284.02497.32362.97-1,464.7545.44
Net Profit
1,525.78789.63472.892,620.091,282.24969.662,302.28366.97
EPS in Rs
5.312.671.858.593.883.207.150.82